Sky Harbour Announces Record Q3 Results and Updates on Leasing, Construction, New Ground Leases and Other Activities Guidance Revised for Year End 2026

Sky Harbour Group (SKYH) reported Q3 earnings, highlighting increased operating expenses and slightly negative operating cash flow due to a $1M interest payment. Assets under construction reached $439M, a record. The Obligated Group saw 87% revenue growth and $3.2M in operating cash flow. The company expects revenue growth from Addison phase II and focuses on 'tier 1' airport acquisitions. Leasing remains a challenge, with 826,000 sq ft to fill in 2027.

Sky Harbour (SKYH) reported Q3 2026 revenues up 45% YoY and 7% sequentially, driven by new campus openings and higher occupancy. Operating expenses rose due to new hires and lease accruals. Cash flow dipped slightly due to a one-time payment. Subsidiary Sky Harbour Capital saw revenues increase 87% YoY and 13% sequentially, with cash flow from operations at $3.2M. The company expects margin expansion as new campuses stabilize and occupancy increases.

Sky Harbour Group (NYSE:SKYH) expects to achieve EBITDA positivity by year-end, driven by its expanding network of private hangar campuses. The company operates eight campuses and has 23 ground leases, with four under construction. It aims to maintain development costs around $300 per square foot. Sky Harbour's debt includes a 2021 issuance at 4.18% and a 4.73% construction facility with JPMorgan. Lease rates at Miami Opa-locka averaged $41 per square foot in phase one and $51 in phase two.

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.